1-7 of 7
Claudia A.M. Stege
Close
Sort by
Journal Articles

Ixazomib, Daratumumab and Low Dose Dexamethasone in Intermediate-Fit Patients with Newly Diagnosed Multiple Myeloma (NDMM); Results of Induction Treatment of the Phase II HOVON 143 Study

Kaz Groen, Claudia A.M. Stege, Kazem Nasserinejad, Koen de Heer, Roel J.W. Van Kampen, Maria B.L. Leijs, Noortje Thielen, Matthijs Westerman, Ka Lung Wu, Inge Ludwig, Djamila Issa, Gerjo A. Velders, Marie-Christiane Vekemans, Niels W.C.J. van de Donk, Gert-Jan Timmers, Pieter Sonneveld, Maarten R. Seefat, Fransien Croon-de Boer, Lidwine W. Tick, Ellen van der Spek, Esther G.M. De Waal, Maaike Sohne, Paula F Ypma, Inger S. Nijhof, Saskia K. Klein, Mark-David Levin, Sonja Zweegman
Journal: Blood
Blood (2021) 138 (Supplement 1): 80.
https://doi.org/10.1182/blood-2021-152112
Published: 2021
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (Ixa Dara dex) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; Results of the Interim Efficacy Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, Ellen van der Spek, MD PhD, Roel J.W. Van Kampen, MD PhD, Maaike Sohne, MD, Noortje Thielen, MD PhD, Yavuz Bilgin, MD PhD, Esther G.M. De Waal, MD, Inge Ludwig, MD MSc, Maria B.L. Leijs, MD, Alain Kentos, MD, Gert Jan Timmers, MD PhD, Koen de Heer, MD, Matthijs Westerman, MD, Marie Christiane Vekemans, Nazik Durdu-Rayman, MD, Nicole C.H.P. van der Burg-de Graauw, MD, Niels W. C. J. Van De Donk, MD PhD, Pieter Sonneveld, Saskia K. Klein, MD PhD, Mark-David Levin, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2019) 134 (Supplement_1): 695.
https://doi.org/10.1182/blood-2019-121694
Published: 2019
Journal Articles

Geriatric Impairments and Low Muscle Mass Are Associated with Treatment Discontinuation and Overall Survival in Newly Diagnosed Non-Transplant Eligible Multiple Myeloma Patients (nte-NDMM) Treated with Dose-Adjusted Melphalan-Prednisone-Bortezomib (MPV) — Results of the Dutch HOVON 123 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Saskia K. Klein, MD PhD, Esther de Waal, PhD, Corien Eeltink, Charlotte L.B.M. Korst, MD, Paula F Ypma, MDPhD, Amanda C. Dijk, MD, Matthijs Westerman, MD, Wendy Deenik, MD, Bea Tanis, PhD, Monique C Minnema, MD PhD, Henk M.W. Verheul, MD PhD, Birgit I. Lissenberg-Witte, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 1889.
https://doi.org/10.1182/blood-2018-99-116920
Published: 2018
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Results from the Randomized Phase II HOVON-126/Nmsg 21#13 Trial

Sonja Zweegman, MDPhD, Fredrik H. Schjesvold, MDPhD, Bronno van der Holt, PhD, Mark-David Levin, MDPhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria B.L. Leijs, MD, Saskia K. Klein, MDPhD, Damian L. Szatkowski, MDPhDMSc, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MDPhD, Asta Svirskaite, Pino Poddighe, MDPhD, Marian Stevens-Kroef, MD, Markus Hansson, MD PhD, Niels WCJ van de Donk, MD PhD, Einar Haukas, MD, Pieter Sonneveld, MDPhD, Niels Abildgaard, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 800.
https://doi.org/10.1182/blood-2018-99-111650
Published: 2018
Journal Articles

Efficacy and Tolerability of Ixazomib, Daratumumab and Low Dose Dexamethasone (IDd) in Unfit and Frail Newly Diagnosed Multiple Myeloma (NDMM) Patients; First Interim Safety Analysis of the Phase II HOVON 143 Study

Claudia A.M. Stege, MD, Kazem Nasserinejad, PhD, Mark-David Levin, MDPhD, Noortje Thielen, MD PhD, Saskia K. Klein, MD PhD, Inge Ludwig, MD MSc, Matthijs Westerman, MD, Paula F Ypma, MDPhD, Yavuz Bilgin, MDPhD, Maaike Sohne, MD, Esther de Waal, PhD, Niels WCJ van de Donk, MD PhD, Pieter Sonneveld, MDPhD, Sonja Zweegman, MDPhD
Journal: Blood
Blood (2018) 132 (Supplement 1): 596.
https://doi.org/10.1182/blood-2018-99-114668
Published: 2018
Journal Articles

Ixazomib-Thalidomide-Low Dose Dexamethasone (ITd) Induction Followed By Maintenance Therapy with Ixazomib or Placebo in Newly Diagnosed Multiple Myeloma Patients Not Eligible for Autologous Stem Cell Transplantation; Initial Results from the Randomized Phase II HOVON-126/Nmsg 21.13 Trial

Sonja Zweegman, MD PhD, Bronno van der Holt, Fredrik H. Schjesvold, MDPhD, Mark-David Levin, PhD, Claudia A.M. Stege, MD, Anders Waage, MD PhD, Maria Berhardina Leijs, MD, Saskia Klein, MD, Damian L. Szatkowski, MDPhDMSc, A Broyl, MDPhD, Per Axelsson, MD, Trung Hieu Do, MD, Dorota Knut-Bojanovska, Ellen van der Spek, MD, Asta Svirskaite, Sonia Cunha, Markus Hansson, MD PhD, Pieter Sonneveld, MDPhD, Einar Haukaas, Niels Abildgaard, MD
Journal: Blood
Blood (2017) 130 (Supplement 1): 433.
https://doi.org/10.1182/blood.V130.Suppl_1.433.433
Published: 2017
Journal Articles

Frailty Predicts Survival and Toxicity in Newly Diagnosed Multiple Myeloma Patients Ineligible for Autologous Stem Cell Transplantation; Report of the HOVON-87/Nmsg-18 Study Group

Claudia A.M. Stege, MD, Bronno van der Holt, Ulf-Henrik Mellqvist, MD, Mark-David Levin, PhD, Morten Salomo, Niels Abildgaard, MD, Gerard Bos, MDPhD, Heleen Visser-Wisselaar, Markus Hansson, MD PhD, Annette van der Velden, MD, Wendy Deenik, MD, Astrid Gruber, MD PhD, Jules L.L.M. Coenen, MD, Torben Plesner, MD, Saskia Klein, MD, Bea Tanis, MD PhD, Damian L. Szatkowski, MDPhDMSc, Rolf Brouwer, MD PhD, Matthijs Westerman, MD, Maria Berhardina Leijs, MD, Harm Sinnige, Einar Haukaas, Klaas van der Hem, MD PhD, Marc Durian, MD, Vera Mattijssen, MD PhD, Peter Gimsing, DO, PhD, Niels WCJ Van De Donk, Marian Stevens-Kroef, PhD, Pieter Sonneveld, MDPhD, Anders Waage, MD PhD, Sonja Zweegman, MD PhD
Journal: Blood
Blood (2017) 130 (Supplement 1): 3146.
https://doi.org/10.1182/blood.V130.Suppl_1.3146.3146
Published: 2017